Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 13/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25346858 | 0.85 | DRD2 (0.33) | DRD2TLR8TLR7 | |
| SCHEMBL25344171 | 0.84 | TLR8 (0.35) | DRD2TLR8 | |
| SCHEMBL25347485 | 0.83 | TLR8 (0.35) | DRD2TLR8TLR7 | |
| SCHEMBL25345902 | 0.79 | TLR8 (0.43) | TLR8IDO1TLR7 | |
| SCHEMBL23289369 | 0.77 | DRD2 (0.34) | DRD2TLR8TLR7 | |
| SCHEMBL31506971 | 0.73 | TLR8 (0.44) | TLR8TLR7 | |
| SCHEMBL22770994 | 0.73 | TLR8 (0.39) | TLR8TLR7 | |
| SCHEMBL25344164 | 0.71 | TLR8 (0.37) | DRD2TLR8 | |
| SCHEMBL22783801 | 0.71 | TLR8 (0.51) | TLR8TLR7 | |
| SCHEMBL25346254 | 0.70 | TLR8 (0.36) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145575-A1 | MACROMOLECULE-SUPPORTED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-05-08 | — | — | US | disclosed |
| US-20250127914-A1 | ANTIBODY-CONJUGATED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2023154307-A1 | ANTIBODY-CONJUGATED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154302-A1 | MACROMOLECULE-SUPPORTED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145575-A1 | MACROMOLECULE-SUPPORTED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES | BRD4, MUS81, ABCC8 | NPSR1 1630/4885DRD2 1737/4885TLR8 1341/4885 |
| US-20250127914-A1 | ANTIBODY-CONJUGATED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES | BCR, CD22, IGSF11 | NPSR1 2228/4885DRD2 951/4885TLR8 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.